Abstract

ABSTRACTFGF23 is an important hormonal regulator of phosphate homeostasis. Together with its co‐receptor Klotho, it modulates phosphate reabsorption and both 1α‐hydroxylation and 24‐hydroxylation in the renal proximal tubules. The most common FGF23‐mediated hypophosphatemia is X‐linked hypophosphatemia (XLH), caused by mutations in the PHEX gene. FGF23‐mediated forms of hypophosphatemia are characterized by phosphaturia and low or low‐normal calcitriol concentrations, and unlike nutritional rickets, these cannot be cured with nutritional vitamin D supplementation. Autosomal dominant and autosomal recessive forms of FGF23‐mediated hypophosphatemias show a similar pathophysiology, despite a variety of different underlying genetic causes. An excess of FGF23 activity has also been associated with a number of other conditions causing hypophosphatemia, including tumor‐induced osteomalacia, fibrous dysplasia of the bone, and cutaneous skeletal hypophosphatemia syndrome. Historically phosphate supplementation and therapy using analogs of highly active vitamin D (eg, calcitriol, alfacalcidol, paricalcitol, eldecalcitol) have been used to manage conditions involving hypophosphatemia; however, recently a neutralizing antibody for FGF23 (burosumab) has emerged as a promising treatment agent for FGF23‐mediated disorders. This review discusses the progression of clinical trials for burosumab for the treatment of XLH and its recent availability for clinical use. Burosumab may have potential for treating other conditions associated with FGF23 overactivity, but these are not yet supported by trial data. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

Highlights

  • Graphical AbstractFGF23 is an important hormonal regulator of phosphate homeostasis

  • Fibroblast growth factors (FGFs) are a diverse family of polypeptides involved with cell signaling that can have autocrine, paracrine, or hormonal activities.[1]

  • FGF23 has been associated with a number of conditions causing hypophosphatemia including x-link hypophosphatemia, tumor-induced osteomalacia, fibrous dysplasia of the bone, cutaneous skeletal hypophosphatemia syndrome, and with a syndrome of hyperphosphatemic familial tumoral calcinosis

Read more

Summary

Graphical Abstract

FGF23 is an important hormonal regulator of phosphate homeostasis. FGF23 has been associated with a number of conditions causing hypophosphatemia including x-link hypophosphatemia, tumor-induced osteomalacia, fibrous dysplasia of the bone, cutaneous skeletal hypophosphatemia syndrome, and with a syndrome of hyperphosphatemic familial tumoral calcinosis. Phosphate supplementation and therapy using analogs of calcitriol (hormonally active vitamin D) have been used to manage conditions involving hypophosphatemia, recently a neutralizing antibody for FGF23 (Burosumab) has emerged as a promising treatment agent for FGF23-mediated disorders. This review discusses the progression of clinical trials for Burosumab for the treatment of XLH and its recent availability for clinical use

Introduction
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.